ADC Therapeutics SA Reports Increased Net Loss of $56.6 Million in Q2 2025, EPS Down to $0.50; Product Revenues Rise to $18.1 Million

Reuters
08/12
<a href="https://laohu8.com/S/ADCT">ADC Therapeutics SA</a> Reports Increased Net Loss of $56.6 Million in <a href="https://laohu8.com/S/QTWO">Q2</a> 2025, EPS Down to $0.50; Product Revenues Rise to $18.1 Million

ADC Therapeutics SA reported its financial results for the second quarter and first half of 2025. The company achieved net product revenues of $18.1 million for the second quarter, slightly up from $17.0 million in the same period in 2024. For the first six months of 2025, net product revenues were $35.5 million, compared to $34.9 million for the same period in the previous year. The increase in product revenues was primarily due to higher sales prices and variability in sales volume. The adjusted net loss for the quarter ended June 30, 2025, was $28.7 million, compared to an adjusted net loss of $24.4 million for the same period in 2024. For the six months ended June 30, 2025, the adjusted net loss was $52.6 million, a decrease from $55.5 million in the first half of 2024. The increase in adjusted net loss for the three-month period was attributed to higher research and development (R&D) costs. R&D expenses rose to $30.1 million for the quarter and $59.0 million for the first half of 2025, up from $24.3 million and $50.0 million, respectively, in the same periods in 2024. The increase was driven by ongoing clinical trials and activities related to new drug candidates. The net loss for the quarter ended June 30, 2025, was $56.6 million, compared to a net loss of $36.5 million for the same period in 2024. For the six months ended June 30, 2025, the net loss was $95.2 million, up from $83.2 million in the first half of 2024. The increased net loss was primarily due to higher R&D expenses and restructuring costs associated with a strategic reprioritization and restructuring plan.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. ADC Therapeutics SA published the original content used to generate this news brief via PR Newswire (Ref. ID: NY48588) on August 12, 2025, and is solely responsible for the information contained therein.

免责声明:投资有风险,本文并非投资建议,以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请,作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考,不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证,投资者应自行研究并在投资前寻求专业建议。

热议股票

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10